Patents by Inventor Sebastian Breuer

Sebastian Breuer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10730938
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: August 4, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • Patent number: 10344085
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 9, 2019
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • Patent number: 10087246
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser
  • Publication number: 20170247440
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser
  • Publication number: 20170247447
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • Publication number: 20170240629
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • Patent number: 7192706
    Abstract: The application discloses a new family of proteins, namely the epsin like proteins (ELP). Said proteins comprise an ENTH domain (Epsin NH2 Terminal Homology domain) and have growth inhibiting activity. The disclosed proteins can be used for the diagnosis of hyperproliferative diseases as well as for gene therapy purposes.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: March 20, 2007
    Assignees: Universität Zürich, The Genetics Company, Inc.
    Inventors: Ernst Hafen, Hugo Stocker, Pierre Daram, Benno Shindelholz, Sebastian Breuer
  • Publication number: 20050164194
    Abstract: The application discloses a new family of proteins, namely the epsin like proteins (ELP). Said proteins comprise an ENTH domain (Epsin NH2 Terminal Homology domain) and have growth inhibiting activity. The disclosed proteins can be used for the diagnosis of hyperproliferative disease as well as for gene therapy purposes.
    Type: Application
    Filed: March 28, 2003
    Publication date: July 28, 2005
    Inventors: Ernst Hafen, Hugo Stocker, Pierre Daram, Benno Schindelholz, Sebastian Breuer